医中誌リンクサービス


文献リスト

1)Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004; 173: 55-68
PubMed CrossRef
医中誌リンクサービス
2)Mabuchi H, Haba T, Tatami R, et al. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N Engl J Med. 1981; 305: 478-82
PubMed CrossRef
医中誌リンクサービス
3)Mabuchi H, Kamon N, Fujita H, et al. Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia. Metabolism. 1987; 36: 475-9
PubMed CrossRef
医中誌リンクサービス
4)Mol MJ, Erkelens DW, Leuven JA, et al. Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia. Lancet. 1986; 2: 936-9
PubMed
医中誌リンクサービス
5)Leclercq V, Harvengt C. Simvastatin (MK 733) in heterozygous familial hypercholesterolemia: a two-year trial. Int J Clin Pharmacol Ther Toxicol. 1989; 27: 76-81
PubMed
医中誌リンクサービス
6)Stalenhoef AF, Mol MJ, Stuyt PM. Efficacy and tolerability of simvastatin (MK-733). Am J Med. 1989; 87: 39S-43S
PubMed
医中誌リンクサービス
7)Leitersdorf E, Eisenberg S, Eliav O, et al. Efficacy and safety of high dose fluvastatin in patients with familial hypercholesterolaemia. Eur J Clin Pharmacol. 1993; 45: 513-8
PubMed CrossRef
医中誌リンクサービス
8)Koizumi J, Haraki T, Yagi K, et al. Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia. Am J Cardiol. 1995; 76: 47A-50A
PubMed CrossRef
医中誌リンクサービス
9)Wierzbicki AS, Lumb PJ, Semra YK, et al. High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia. QJM. 1998; 91: 291-4
PubMed CrossRef
医中誌リンクサービス
10)Hoogerbrugge N. Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia. J Intern Med. 1998; 244: 143-7
PubMed CrossRef
医中誌リンクサービス
11)Kajinami K, Koizumi J, Ueda K, et al. Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 Study Group. Am J Cardiol. 2000; 85: 178-83
PubMed CrossRef
医中誌リンクサービス
12)Noji Y, Higashikata T, Inazu A, et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2002; 163: 157-64
PubMed CrossRef
医中誌リンクサービス
13)Ballantyne CM. Familial hypercholesterolaemia: optimum treatment strategies. Int J Clin Pract Suppl. 2002; 130: 22-6
PubMed
医中誌リンクサービス
14)Mabuchi H, Nohara A, Higashikata T, et al. Clinical efficacy and safety of rosuvastatin in Japanese patients with heterozygous familial hypercholesterolemia. J Atheroscler Thromb. 2004; 11: 152-8
医学中央雑誌刊行会  PubMed CrossRef
医中誌リンクサービス
15)寺本民生.スタチンの安全性評価と臨床的意義―米国NLAレポートより―.薬理と治療.2006; 34: 931-5
医学中央雑誌刊行会
医中誌リンクサービス
16)Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J. 2004; 148: 447-55
PubMed CrossRef
医中誌リンクサービス
17)Kosasayama A, Yoshida M, Okada S. Post-marketing surveillance of probucol (Sinlestal) in Japan. Artery. 1992; 19: 147-61
PubMed
医中誌リンクサービス
18)Anderson JL, Schroeder JS. Effects of probucol on hyperlipidemic patients with cardiac allografts. J Cardiovasc Pharmacol. 1979; 1: 353-65
PubMed CrossRef
医中誌リンクサービス
19)Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med. 2004; 350: 1579-82
PubMed CrossRef
医中誌リンクサービス
20)Naito C, Yamamoto A, Saito Y, et al. Long term effect of LDL apheresis in Japan. LDL Apheresis Study Group. Biomater Artif Cells Immobilization Biotechnol. 1991; 19: 19-26
PubMed
医中誌リンクサービス
21)Koga N, Iwata Y, Yamamoto A. Angiographic and pathological studies on regression of coronary atherosclerosis of FH patients who received LDL-apheresis treatment. Artif Organs. 1992; 16: 171-6
医中誌リンクサービス
22)Tatami R, Inoue N, Itoh H, et al. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS Investigators. Atherosclerosis. 1992; 95: 1-13
PubMed CrossRef
医中誌リンクサービス
23)Takahashi T, Nakano S, Shimazaki Y, et al. Long-term appraisal of coronary bypass operations in familial hypercholesterolemia. Ann Thorac Surg. 1993; 56: 499-505
PubMed CrossRef
医中誌リンクサービス
24)Yamamoto A, Harada-Shiba M, Kawaguchi A, et al. Apheresis technology for prevention and regression of atherosclerosis. Ther Apher. 2001; 5: 221-5
PubMed CrossRef
医中誌リンクサービス
25)Tasaki H, Yamashita K, Saito Y, et al. Low-density lipoprotein apheresis therapy with a direct hemoperfusion column: a Japanese multicenter clinical trial. Ther Apher Dial. 2006; 10: 32-41
医学中央雑誌刊行会  PubMed
医中誌リンクサービス
26)Mabuchi H, Koizumi J, Shimizu M, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol. 1998; 82: 1489-95
PubMed CrossRef
医中誌リンクサービス
27)Nishimura S, Sekiguchi M, Kano T, et al. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis. 1999; 144: 409-17
PubMed CrossRef
医中誌リンクサービス
28)Matsuzaki M, Hiramori K, Imaizumi T, et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J Am Coll Cardiol. 2002; 40: 220-7
CrossRef
医中誌リンクサービス
29)Kroon AA, Aengevaeren WR, van der Werf T, et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation. 1996; 93: 1826-35
PubMed CrossRef
医中誌リンクサービス
30)Levy RI, Fredrickson DS, Stone NJ, et al. Cholestyramine in type II hyperlipoproteinemia. A double-blind trial. Ann Intern Med. 1973; 79: 51-8
PubMed CrossRef
医中誌リンクサービス
31)Uauy R, Vega GL, Grundy SM, et al. Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover. J Pediatr. 1988; 113: 387-92
PubMed CrossRef
医中誌リンクサービス
32)Malloy MJ, Kane JP, Kunitake ST, et al. Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia. Ann Intern Med. 1987; 107: 616-23
PubMed CrossRef
医中誌リンクサービス
33)Yamamoto A, Harada-Shiba M, Kawaguchi A, et al. The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy. Atherosclerosis. 2000; 153: 89-98
PubMed CrossRef
医中誌リンクサービス
34)Yamamoto A, Matsuzawa Y, Kishino B, et al. Effects of probucol on homozygous cases of familial hypercholesterolemia. Atherosclerosis. 1983; 48: 157-66
PubMed CrossRef
医中誌リンクサービス
35)Baker SG, Joffe BI, Mendelsohn D, et al. Treatment of homozygous familial hypercholesterolaemia with probucol. S Afr Med J. 1982; 62: 7-11
PubMed
医中誌リンクサービス
36)Jones DB, Simpson HC, Slaughter P, et al. A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolaemia. Atherosclerosis. 1984; 53: 1-7
PubMed CrossRef
医中誌リンクサービス
37)Buckley MM, Goa KL, Price AH, et al. Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs. 1989; 37: 761-800
PubMed CrossRef
医中誌リンクサービス
38)Yamamoto A, Harada-Shiba M, Endo M, et al. The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy. Atherosclerosis. 2006; 186: 126-31
PubMed CrossRef
医中誌リンクサービス
39)Stefanutti C, Di Giacomo S, Vivenzio A, et al. Low-density lipoprotein apheresis in a patient aged 3.5 years. Acta Paediatr. 2001; 90: 694-701
PubMed CrossRef
医中誌リンクサービス
40)Makino H, Harada-Shiba M. Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia. Ther Apher Dial. 2003; 7: 397-401
医学中央雑誌刊行会  PubMed
医中誌リンクサービス
41)de Gennes JL, Touraine R, Maunand B, et al. [Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis ans heroic treatment]. Bull Mem Soc Med Hop Paris. 1967; 118: 1377-402
PubMed
医中誌リンクサービス
42)Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet. 1975; 1: 1208-11
PubMed
医中誌リンクサービス
43)Thompson GR, Myant NB, Kilpatrick D, et al. Assessment of long-term plasma exchange for familial hypercholesterolaemia. Br Heart J. 1980; 43: 680-8
PubMed CrossRef
医中誌リンクサービス
44)Stein EA, Adolph R, Rice V, et al. Nonprogression of coronary artery atherosclerosis in homozygous familial hypercholesterolemia after 31 months of repetitive plasma exchange. Clin Cardiol. 1986; 9: 115-9
PubMed CrossRef
医中誌リンクサービス
45)Berger GM, Miller JL, Bonnici F, et al. Continuous flow plasma exchange in the treatment of homozygous familial hypercholesterolemia. Am J Med. 1978; 65: 243-51
PubMed CrossRef
医中誌リンクサービス
46)Graisely B, Cloarec M, Salmon S, et al. Extracorporeal plasma therapy for homozygous familial hypercholesterolaemia. Lancet. 1980; 2: 1147
PubMed
医中誌リンクサービス
47)King ME, Breslow JL, Lees RS. Plasma-exchange therapy of homozygous familial hypercholesterolemia. N Engl J Med. 1980; 302: 1457-9
PubMed CrossRef
医中誌リンクサービス
48)Mimori A, Takahashi K, Mitamura T, et al. Clinical evaluation of three types of plasmapheresis in a patient with type IIa familial hypercholesterolemia. J Clin Apher. 1987; 3: 209-15
PubMed CrossRef
医中誌リンクサービス
49)Yamamoto A, Yokoyama S, Satani M, et al. Evaluation of selective LDL-removal in the treatment of familial hypercholesterolemia: double membrane filtration and adsorption system. Prog Clin Biol Res. 1988; 255: 357-66
PubMed
医中誌リンクサービス
50)Suzuki M, Yamane S, Matsugane T, et al. Evaluation of double filtration plasmapheresis, thermofiltration, and low-density lipoprotein adsorptive methods by crossover test in the treatment of familial hypercholesterolemia patients. Artif Organs. 1996; 20: 296-302
医中誌リンクサービス
51)Mabuchi H, Michishita I, Sakai T, et al. Treatment of homozygous patients with familial hypercholesterolemia by double-filtration plasmapheresis. Atherosclerosis. 1986; 61: 135-40
PubMed CrossRef
医中誌リンクサービス
52)Leitman SF, Smith JW, Gregg RE. Homozygous familial hypercholesterolemia. Selective removal of low-density lipoproteins by secondary membrane filtration. Transfusion. 1989; 29: 341-6
PubMed CrossRef
医中誌リンクサービス
53)Thompson GR. Plasma exchange for hypercholesterolaemia. Lancet. 1981; 1: 1246-8
PubMed
医中誌リンクサービス
54)Yokoyama S, Hayashi R, Kikkawa T, et al. Specific sorbent of apolipoprotein B-containing lipoproteins for plasmapheresis. Characterization and experimental use in hypercholesterolemic rabbits. Arteriosclerosis. 1984; 4: 276-82
PubMed
医中誌リンクサービス
55)Yokoyama S, Hayashi R, Satani M, et al. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis. 1985; 5: 613-22
PubMed
医中誌リンクサービス
56)Kojima S, Harada-Shiba M, Yamamoto A. Plasma constituents other than low-density lipoprotein adsorbed by dextran-sulfate column. Ther Apher. 1997; 1: 309-13
PubMed CrossRef
医中誌リンクサービス
57)Bambauer R, Olbricht CJ, Schoeppe E. Low-density lipoprotein apheresis for prevention and regression of atherosclerosis: clinical results. Ther Apher. 1997; 1: 242-8
PubMed CrossRef
医中誌リンクサービス
58)Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012; 380: 1995-2006
PubMed CrossRef
医中誌リンクサービス
59)Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012; 380: 2007-17
PubMed CrossRef
医中誌リンクサービス
60)Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012; 308: 2497-506
PubMed CrossRef
医中誌リンクサービス
61)Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012; 126: 2408-17
PubMed CrossRef
医中誌リンクサービス
62)Yamamoto T, Harada-Shiba M, Nakatani M, et al. Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice. Mol Ther Nucleic Acids. 2012; 1: e22
医中誌リンクサービス
63)Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 375: 998-1006
PubMed CrossRef
医中誌リンクサービス
64)Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol. 2010; 105: 1413-9
PubMed CrossRef
医中誌リンクサービス
65)Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012; 126: 2283-92
PubMed CrossRef
医中誌リンクサービス
66)Akdim F, Stroes ES, Sijbrands EJ, et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol. 2010; 55: 1611-8
PubMed CrossRef
医中誌リンクサービス
67)Thomas GS, Cromwell WC, Ali S, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013; 62: 2178-84
PubMed CrossRef
医中誌リンクサービス
68)Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2012; 33: 1142-9
PubMed CrossRef
医中誌リンクサービス
69)Samaha FF, McKenney J, Bloedon LT, et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2008; 5: 497-505
PubMed CrossRef
医中誌リンクサービス
70)Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007; 356: 148-56
PubMed CrossRef
医中誌リンクサービス
71)Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013; 381: 40-6
PubMed CrossRef
医中誌リンクサービス


NPO医学中央雑誌刊行会
https://www.jamas.or.jp/
info@jamas.or.jp